INVA

Innoviva, Inc. NASDAQ Listed Oct 5, 2004

Healthcare ·Biotechnology ·US · inva.com

$22.80

Mkt Cap $1.5B

52w Low $16.52 72.8% of range 52w High $25.15

50d MA $22.97 200d MA $20.63

P/E (TTM) 5.8x

EV/EBITDA 2.8x

P/B 1.3x

Debt/Equity 0.2x

ROE 23.1%

P/FCF 6.9x

RSI (14) —

ATR (14) —

Beta 0.40

50d MA $22.97

200d MA $20.63

Avg Volume 764.4K

Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

SIC Code

2834

CIK (SEC)

1080014

Phone

650 238 9600

1350 Old Bayshore Highway · Burlingame, CA 94010 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
May 6, 2026	AMC	0.43	2.22	+416.3%	22.52	+4.3%	+1.2%	—	—	—	—	—
Feb 25, 2026	AMC	0.34	1.94	+470.6%	24.24	+3.1%	-2.9%	-2.5%	-0.6%	-2.3%	+1.9%	—
Nov 5, 2025	AMC	0.46	1.08	+134.8%	18.23	+8.9%	+12.9%	+1.4%	+0.0%	+4.9%	+1.7%	—
Aug 6, 2025	AMC	0.57	0.77	+35.1%	18.25	+0.1%	+1.2%	-0.7%	+7.1%	+2.2%	+2.6%	—
May 7, 2025	AMC	0.29	0.25	-13.8%	18.74	+0.1%	-0.9%	-0.1%	+0.3%	-1.9%	-1.4%	—
Feb 26, 2025	AMC	0.34	0.57	+67.6%	17.90	+0.8%	-2.0%	+2.1%	-0.7%	-1.2%	+0.2%	—
Nov 6, 2024	AMC	0.27	0.02	-92.6%	19.92	-0.2%	+0.4%	+0.9%	-0.3%	+1.0%	-1.1%	—
Jul 31, 2024	AMC	0.24	0.68	+183.3%	18.84	-4.4%	+2.4%	-1.1%	-4.0%	+0.3%	-1.3%	—
May 8, 2024	AMC	0.17	0.46	+170.6%	15.56	+0.6%	-1.7%	+2.0%	+3.8%	-0.5%	-1.7%	—
Feb 29, 2024	AMC	0.23	0.76	+230.4%	15.28	+9.0%	-0.3%	+0.1%	-2.5%	+2.0%	-0.7%	—
Nov 1, 2023	AMC	0.27	0.98	+263.0%	12.42	+6.6%	+6.9%	+2.6%	+0.1%	+0.3%	+0.5%	—
Aug 2, 2023	AMC	0.26	0.08	-69.2%	13.18	-0.6%	+0.0%	+3.0%	-0.2%	+0.9%	+0.0%	—
May 9, 2023	AMC	0.23	0.42	+82.6%	11.56	+1.7%	+5.5%	+1.9%	+1.9%	+1.9%	+2.6%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Feb 26	BTIG	Maintains	Buy → Buy	—	$24.24	$25.00	+3.1%	-2.9%	-2.5%	-0.6%	-2.3%	+1.9%
Dec 16	HC Wainwright & Co.	Maintains	Buy → Buy	—	$20.14	$20.71	+2.8%	-1.1%	+0.7%	+0.1%	-0.4%	+0.0%
Nov 6	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$18.23	$19.85	+8.9%	+12.9%	+1.4%	+0.0%	+4.9%	+1.7%
Aug 11	HC Wainwright & Co.	Maintains	Buy → Buy	—	$18.34	$18.96	+3.4%	+7.1%	+2.2%	+2.6%	+1.3%	+0.2%
May 10	EF Hutton	Maintains	Buy → Buy	—	$11.56	$11.76	+1.7%	+5.5%	+1.9%	+1.9%	+1.9%	+2.6%
Apr 20	EF Hutton	Maintains	Buy → Buy	—	$11.85	$11.85	+0.0%	-0.1%	+1.2%	-1.5%	-0.6%	+1.2%
Mar 3	EF Hutton	Maintains	Buy → Buy	—	$10.93	$10.93	+0.0%	+0.5%	+0.3%	-1.2%	+0.6%	-2.1%
Mar 3	Goldman Sachs	Maintains	Neutral → Neutral	—	$10.93	$10.93	+0.0%	+0.5%	+0.3%	-1.2%	+0.6%	-2.1%
Mar 3	Morgan Stanley	Maintains	Underweight → Underweight	—	$10.93	$10.93	+0.0%	+0.5%	+0.3%	-1.2%	+0.6%	-2.1%
Jan 24	Morgan Stanley	Maintains	Underweight → Underweight	—	$12.94	$12.73	-1.6%	-3.9%	-0.1%	+2.1%	+0.1%	-1.7%
Oct 13	Morgan Stanley	Maintains	Underweight → Underweight	—	$12.95	$12.91	-0.3%	+3.2%	-1.0%	+2.2%	+1.1%	-1.8%
Aug 8	Morgan Stanley	Maintains	Underweight → Underweight	—	$14.44	$14.46	+0.1%	+2.4%	-2.8%	+0.9%	-0.2%	+1.9%
Jul 20	Goldman Sachs	Maintains	Neutral → Neutral	—	$14.72	$14.57	-1.0%	-2.1%	+2.9%	-1.8%	+0.0%	-0.5%
Jul 15	Morgan Stanley	Maintains	Underweight → Underweight	—	$14.58	$14.61	+0.2%	-1.2%	+0.8%	+1.4%	-2.1%	+2.9%
Apr 12	Morgan Stanley	Maintains	Underweight → Underweight	—	$19.15	$19.27	+0.6%	+1.5%	-0.7%	-1.4%	-2.6%	-2.5%
Feb 23	Morgan Stanley	Maintains	Underweight → Underweight	—	$19.19	$19.76	+3.0%	-0.1%	+0.5%	+0.6%	-0.9%	-2.8%
Feb 11	EF Hutton	Maintains	Buy → Buy	—	$18.00	$17.81	-1.1%	+6.9%	+2.4%	-0.1%	+2.8%	-1.5%
Nov 11	Morgan Stanley	Maintains	Underweight → Underweight	—	$10.65	$10.82	+1.6%	+1.7%	-0.7%	+2.6%	-1.5%	+1.5%
Apr 27	Stifel	Maintains	Hold → Hold	—	$14.46	$14.31	-1.0%	-1.6%	+1.9%	+0.7%	-1.0%	-0.5%
Apr 27	Stifel Nicolaus	Maintains	Hold → Hold	—	$14.46	$14.31	-1.0%	-1.6%	+1.9%	+0.7%	-1.0%	-0.5%
Nov 20	Deutsche Bank	Maintains	Hold → Hold	—	$13.06	$13.04	-0.2%	+0.8%	+1.8%	+0.1%	-1.2%	-1.1%
Oct 6	Morgan Stanley	Maintains	Underweight → Underweight	—	$14.75	$14.75	+0.0%	-2.9%	-1.1%	-1.6%	-0.8%	+0.5%
Oct 31	Cowen & Co.	Upgrade	Market Perform → Outperform	—	$9.60	$9.90	+3.1%	+7.3%	-1.3%	-2.8%	-5.3%	+2.9%

Data updated apr 25, 2026 3:54pm · Source: massive.com